Aquinox Pharmaceuticals

Aquinox Pharmaceuticals Inc. is a Vancouver-based pharmaceutical company that has been dedicated to discovering and developing small molecule therapeutics since its establishment in 2004. With a focus on treating cancer and inflammatory diseases, the company's product portfolio includes AQX-MN100, a medication designed for these purposes. Additionally, Aquinox has a SH2-containing inositol 5'-phosphatase inhibition program aimed at aiding in blood cell recovery. The company received a significant $75.40M Post-IPO Equity investment on 20 September 2016. As the company operates in the Biotechnology, Health Care, and Health and Wellness industries, its innovative approach to treating critical diseases presents a compelling opportunity for investors seeking to support breakthrough advancements in the healthcare sector.